Document is current
Any future updates will be listed below
-
Authors
Totsch, Stacie K.
Schlappi, Charles
Kang, Kyung-Don
Ishizuka, Andrew S. https://orcid.org/0000-0002-3024-7536
Lynn, Geoffrey M.
Fox, Brandon
Beierle, Elizabeth A.
Whitley, Richard J.
Markert, James M.
Gillespie, G. Yancey
Bernstock, Joshua D.
Friedman, Gregory K.
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | U.S. Food and Drug Administration (R01FD005379)
U.S. Department of Defense (W81XWH-15-1-0108)
Hyundai Motor Group | Hyundai Motor America | Hyundai Hope On Wheels
Rally Foundation for Childhood Cancer Research Kaul Pediatric Research Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute (T32CA183926, R01CA217179, R01CA217179)
American Brain Tumor Association
UAB Medical Scientist Training Program
- License Information
-
More Information
Article History
Received: 17 April 2019
Revised: 21 June 2019
Accepted: 22 June 2019
First Online: 9 July 2019
Compliance with ethical standards
:
: JMM, RJW, and GYG are founders of and own stock and stock options (<8% interest) in Aettis, Inc., a biotech company that holds intellectual property surrounding oHSV. GYG currently serves as one of five unpaid members of the Board of Directors for Aettis, Inc. JMM, RJW, and GYG were also founders of and owned stock and stock options (<8%) in Catherex Inc., a biotechnology company that had licensed additional intellectual property related to oHSV. Catherex, Inc., was sold to Amgen, Inc., on 18 December 2015, and they no longer participate in any decision making or have any control of any aspect of Catherex or Amgen, although they did receive proceeds from the sale of the company. GYG has served as a paid advisor to a Program Project at the Ohio State University that seeks to find improved methods for application of distinct oHSV to treat localized and metastatic cancers. This is generally, but not specifically, related to the subject matter of this investigation. JDB has positions/equity in CITC Ltd. JDB, ASI, and GML have positions/equity Avidea Technologies. RJW is a member of the Board of Directors of Gilead Sciences. The remaining authors declare that they have no conflict of interest.
